Evonik has posted first-quarter group sales up 7% year-on-year to EUR3.4bn (US$3.8bn), with an improvement in adjusted EBITDA to EUR650m, up 40%.

The outlook for fiscal 2015 has been raised, with sales slightly above the prior year and adjusted EBITDA expected to be at least EUR2.2bn.

“The positive trend observed in the second half of 2014 has continued,” said Evonik chairman, Klaus Engel.

“Looking at our clear earnings increase, it is pleasing to see three quarters of our 22 business lines were able to improve their earnings year-on-year.

“We should exceed the targets previously forecast for 2015.”